Dr. Redig is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
75 Francis St
Boston, MA 02115Phone+1 617-732-5500
Education & Training
Brigham and Women's Hospital/Massachusetts General Hospital/Dana-Farber Cancer InstituteFellowship, Hematology and Medical Oncology, 2013 - 2017- Brigham and Women's HospitalResidency, Internal Medicine, 2010 - 2013
Northwestern University The Feinberg School of MedicineClass of 2010
Certifications & Licensure
MA State Medical License 2012 - 2025- American Board of Internal Medicine Internal Medicine
- American Board of Internal Medicine Medical Oncology
Clinical Trials
- Osimertinib and Gefitinib in EGFR Inhibitor naïve Advanced EGFR Mutant Lung Cancer Start of enrollment: 2017 May 09
- Nivolumab in Combination With Chemotherapy, or Nivolumab in Combination With Ipilimumab, in Advanced EGFR-Mutant or ALK-Rearranged NSCLC Start of enrollment: 2017 Nov 22
Publications & Presentations
PubMed
- 152 citationsBiochemical role of the collagen-rich tumour microenvironment in pancreatic cancer progression.Mario A. Shields, Surabhi Dangi-Garimella, Amanda J. Redig, Hidayatullah G. Munshi
The Biochemical Journal. 2012-01-15 - 1102 citationsAdaptive resistance to therapeutic PD-1 blockade is associated with upregulation of alternative immune checkpoints.Shohei Koyama, Esra A. Akbay, Yvonne Y. Li, Grit S. Herter-Sprie, Kevin A. Buczkowski
Nature Communications. 2016-02-17 - 199 citationsBasket Trials and the Evolution of Clinical Trial Design in an Era of Genomic MedicineAmanda J. Redig, Pasi A. Jänne
Journal of Clinical Oncology. 2015-02-09
Press Mentions
Effect of Erlotinib plus Bevacizumab vs Erlotinib Alone on Progression-Free Survival in Patients with Advanced EGFR-Mutant Non-Small Cell Lung Cancer: A Phase 2 Randomized Clinical TrialAugust 8th, 2019
On the Road at ASCO 2023: Key Takeaways, Observations and ReflectionsJuly 13th, 2023
Grant Support
- The Protein Kinase C Pathway In Acute LeukemiaNational Institute Of Environmental Health Sciences2007–2009
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
